# Bone health up to five years after Roux-en-Y gastric bypass: a cross-sectional study during the COVID-19 pandemic

## TL;DR

This study examines bone health in obese patients up to five years after Roux-en-Y gastric bypass surgery, finding significant changes in bone density and related biomarkers.

## Contribution

The study provides new insights into long-term bone health risks following Roux-en-Y gastric bypass surgery.

## Key findings

- Half of the patients showed altered vitamin D and parathyroid hormone levels up to five years after surgery.
- Bone density was reduced in 14 and 15 patients in the lumbar and femoral regions, respectively.
- Three patients exhibited unequivocal alterations in bone densitometry.

## Abstract

To evaluate bone health in obese patients undergoing surgery using the Roux-en-Y gastric bypass (RYGB) technique.

In a sample of 22 obese patients undergoing RYGB surgery, evaluation of bone densitometry (BD) and plasma levels of calcium, phosphorus, magnesium, vitamin D (VITD), parathyroid hormone (PTH), alkaline phosphatase, and albumin was performed.

Signs of potential changes in calcification were detected in plasma tests, expressed as a decrease in VITD (46.4%) and an increase in PTH (50%). Three patients presented with bone framework damage. BD was unequivocally altered in three patients. A decrease in bone density was observed in 14 and 15 patients in the lumbar and femoral regions, respectively.

Although PTH and VITD dosages did not show a direct correlation with BD, it was observed that approximately half of the patients had altered dosages of these hormones up to five years after surgery, and there was damage to the bone health expressed by BD. Loss to follow-up may have contributed to the increased risk of developing metabolic bone disease.